Results of Operations and Financial Condition. On August 6, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor s…

Director — Ron Philip: Mr. Ron Philip was appointed to the Board of Directors and will serve on specific committees.

Amendments to employment agreements for potential severance and change in control benefits.

Unregistered Sales of Equity Securities. On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per shar…

Material Modification to rights of Security Holders. To the extent required by

The filing pertains to equity plan amendments, not a management change.

Results of Operations and Financial Condition. On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor sh…

of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements…

Entry into a Material Definitive Agreement On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“C…

Results of Operations and Financial Condition. In connection with the Offering, the Company filed the Prospectus Supplement with the SEC, which contains certain information regarding the Company’s results of operations or financial condition for the quarter ended March 31, 2026, as set forth below. As of March 31, 2026, the Company estimates that it had cash, cash equivalents and short-term investments of approximately $82.0 million. This financial data as of March 31, 2026 is preliminary and…

Entry into a Material Definitive Agreement. On April 26, 2026 (the “ Effective Date ”), Avalo Therapeutics, Inc. (the “ Company ”) entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization (the “ Milestone Buyout and Amendment Agreement ”). As previously disclosed, the Company, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, AlmataBio, Inc. (“ AlmataBio ”) and Patrick J. Crutcher, solely in his capacity as the rep…

Director — Dr. Jonathan Goldman and Mitchell Chan: Dr. Jonathan Goldman and Mitchell Chan decided not to stand for re-election to the Board at the Company’s 2026 Annual Meeting.

Results of Operations and Financial Condition. On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor…

of this Current Report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the year ended December 31, 2025. The Company’s actual results for the year ended December 31, 2025 will be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and may differ materially from the above estimate. The information conta…

Results of Operations and Financial Condition. On November 6, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise…

Chief Business Officer — Taylor Boyd: Avalo Therapeutics, Inc. appointed Taylor Boyd as Chief Business Officer.

Director — Kevin Lind: Kevin Lind was appointed as a director and will join the Audit Committee.

Results of Operations and Financial Condition. On August 7, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…

Director — Rita Jain, M.D.: Dr. Rita Jain was appointed to the Board of Directors.

Termination of a Material Definitive Agreement. As previously disclosed in May 2023, the Company entered into a Sales Agreement with Oppenheimer & Co. Inc. (“Oppenheimer”) as sales agent, which the Company and Oppenheimer amended in August 2023 (as amended, the “Initial Agreement”), pursuant to which the Company was permitted to offer and sell, from time to time through Oppenheimer, shares of the Company’s common stock having an aggregate offering price of up to $50.0 million. On June 3, 2025…

Entry into a Material Definitive Agreement. On June 5, 2025, Avalo Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $75.0 million (the “Offering”). The issuance and sale of shares in the Offering, if any, by…

Results of Operations and Financial Condition. On May 12, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject…

Chairman of the Board, Director — Michael Heffernan: Appointment of a new Chairman and Director.

Results of Operations and Financial Condition. On March 20, 2025, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or…

Chief Strategy Officer — Jennifer Riley: Avalo Therapeutics appointed Jennifer Riley as Chief Strategy Officer, bringing significant biotech leadership experience.